Alpha Tau Reports Strong Early Responses in Glioblastoma Trial

Share on Social Media

Alpha Tau Medical Alpha DaRT therapy for recurrent glioblastoma showing tumour response findings from the REGAIN trial.
Image: Pixels

Alpha Tau reports a 100% objective response rate among six evaluable patients in the REGAIN trial of Alpha DaRT for recurrent glioblastoma, including five complete responses.

Written By: Anshu Gupta, PharmD

Reviewed By: Pharmacally Editorial Team

Alpha Tau Medical Ltd. announced updated interim results on November 15, 2026, from its U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial evaluating Alpha DaRT® in patients with recurrent glioblastoma (GBM). The findings were presented by investigators from The Ohio State University Comprehensive Cancer Center (OSUCCC – James) at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO), held November 12–15, 2026, in Philadelphia.

The analysis, based on data collected through November 11, included eight treated patients, six of whom had reached MRI response assessment. The remaining two patients had not yet reached response assessment. The study’s primary endpoints are procedural feasibility and safety, while tumour response and survival provide additional information on treatment activity.

Tumour Response and Survival Outcomes

Measured as best overall response using Response Assessment in Neuro-Oncology (RANO) criteria, all six evaluable patients (100%) achieved an objective response. Five patients (83.3%) achieved complete responses, with no measurable tumour remaining at the treated site, while one patient (16.7%) achieved a partial response, with a 58% reduction in tumour measurements.

Of these responses, three complete responses (50% of evaluable patients) have been confirmed. The updated analysis showed that the first three patients previously reported in May 2026 had all achieved confirmed complete responses. Two had initially achieved complete responses, while the third had initially shown stable disease before achieving a confirmed complete response following longer follow-up. The three more recently assessed patients demonstrated two early complete responses and one partial response, which remain subject to confirmation on subsequent MRI scans.

All eight treated patients remained alive as of November 11, 2026. Among the six evaluable patients, median follow-up from trial enrolment was 6.9 months (range: 3.1–11.6 months). Median overall survival (OS) had not been reached, and three patients had been followed for more than eight months.

No definitive recurrence within the treated area had been reported in any patient at the data cutoff. However, the first patient treated subsequently developed tumour progression outside the treated area approximately nine months after treatment, despite remaining free of recurrence at the treated site. The patient subsequently received additional therapy.

Treatment Feasibility and Safety

Successful deployment of all planned Alpha DaRT sources was achieved in all eight treated patients, representing 100% procedural feasibility. No unanticipated serious adverse events (SAEs) had been reported.

One Grade 3 SAE, previously disclosed in May 2026, involved a seizure accompanied by Todd’s paralysis in a patient with a prior history of seizures. The event required a 48-hour hospital stay and resolved following steroid treatment. According to the company, patients recovered from adverse events without residual procedure-related symptoms.

Follow-up imaging identified necrosis or suspected necrosis in or around the treated area in four of the six evaluable patients. These findings were asymptomatic and were not classified as SAEs. The company described radiation necrosis as a known effect of focal radiation, particularly in previously irradiated brain tissue.

In two of these patients, scans obtained approximately three months after treatment also showed new or increased enhancement adjacent to or outside the treated area. Investigators have not yet determined whether these findings represent radiation necrosis or tumour progression. Additional imaging and, where necessary, biopsy are planned to clarify their nature.

Alpha DaRT Technology and Updated Trial Design

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is an intratumoral radiation approach that uses radium-224-impregnated sources placed directly within solid tumours. As radium-224 decays, its short-lived daughter atoms are released and disperse while emitting high-energy alpha particles intended to destroy tumour cells. Their short diffusion range is designed to concentrate radiation within the tumour while limiting exposure to surrounding healthy tissue.

For intracranial treatment, Alpha Tau developed a specialised stereotactic delivery system that enables image-guided placement of the sources through minimally invasive burr-hole access without requiring an open craniotomy. Treatment in REGAIN was performed at OSUCCC – James by a multidisciplinary team led by principal investigator and radiation oncologist Joshua D. Palmer, MD.

REGAIN is a prospective, open-label, single-arm, multicentre study designed to enrol up to 20 U.S. patients with recurrent glioblastoma or IDH-mutant grade 4 tumours that are not amenable to surgical resection and who have previously received CNS radiation (NCT06910306).

In October 2026, the FDA approved an Investigational Device Exemption (IDE) supplement expanding the trial from 10 to 20 patients across three U.S. academic cancer centres. The amended protocol also added progression-free survival as a secondary endpoint, introduced regular quality-of-life assessments and provided for an additional interim analysis.

Alpha DaRT remains investigational for recurrent glioblastoma and has not received FDA marketing approval for this indication.

Clinical Interpretation

The interim findings demonstrate consistent procedural feasibility across all eight treated patients and preliminary tumour responses in all six evaluable patients. Five complete responses and one partial response represent encouraging observations in recurrent glioblastoma. However, only three complete responses have been confirmed, while the remaining early responses require subsequent imaging.

The small evaluable population, limited follow-up and absence of a comparator group restrict conclusions about clinical efficacy and long-term survival benefit. The distinction between best overall response and confirmed response is important when interpreting the reported 100% objective response rate.

The unresolved imaging findings also require careful interpretation. Distinguishing radiation necrosis from tumour progression is essential for assessing treatment response and local disease control. Furthermore, progression outside the treated area in one patient highlights the importance of evaluating disease control beyond the treatment site. Longer follow-up will be necessary to establish response durability and the clinical significance of these findings.

References

New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events – Conference Call Scheduled for 8:30am ET November 16, AlphaTau, 15 November 2026

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma, ClinicalTrials.gov ID NCT06910306

PharmD Intern

About the Writer

Anshu Gupta (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, regulatory affairs, and medical writing. She has presented research at academic conferences and completed certifications in Good Clinical Practice (GCP), ICH-GCP, and drug safety. Passionate about clinical trials and evidence-based medicine, she is committed to translating scientific evidence into accurate, reliable, and accessible healthcare content.


Share on Social Media
Scroll to Top